据BusinessWire报道，人工智能个性化手术医疗科技公司Carlsmed，近日宣布完成由B Capital和US Venture Partners共同领投的5250万美元C轮融资。此轮融资将主要用于加速其腰椎融合手术的aprevo®个性化脊柱手术平台的商业化进程，以及用于颈椎融合手术的aprevo®的开发工作，据悉，aprevo®平台将于2025年正式推出。
Carlsmed是一家致力于利用人工智能技术为患者提供个性化手术解决方案的医疗科技公司。其核心产品aprevo®平台，通过结合人工智能技术和先进的医疗设备，为医生提供了一种更加精准、高效的脊柱手术方案。目前，该平台已成功应用于腰椎融合手术，并取得了显著的治疗效果。
此轮融资的领投方B Capital和US Venture Partners表示，他们非常看好Carlsmed的发展前景，并相信Carlsmed的产品和技术将会在医疗领域产生深远的影响。B Capital的合伙人表示：“Carlsmed正在改变脊柱手术的方式，使其更加精准、高效。我们相信，Carlsmed的技术将会成为未来医疗领域的重要趋势。”
Carlsmed的CEO表示，此轮融资将主要用于推动aprevo®平台的商业化进程，以及开发新的产品。他还表示，Carlsmed将继续致力于研发先进的人工智能医疗技术，为患者提供更加个性化的手术解决方案。
随着人工智能技术在医疗领域的不断深入，Carlsmed的发展潜力被广泛看好。此轮融资的成功，不仅为Carlsmed提供了充足的资金支持，也为其未来的发展奠定了坚实的基础。
英语如下：
**News Title:** “Carlsmed Completes $52.5 Million Series C Financing to Advance AI-Personalized Medical Technology”
**Keywords:** Carlsmed, Series C financing, personalized surgery, medical technology
**News Content:** # **Carlsmed, an AI-powered personalized surgical medical technology company, completes $52.5 million Series C financing**
According to BusinessWire, Carlsmed, an AI-powered personalized surgical medical technology company, recently announced the completion of a $52.5 million Series C financing round led by B Capital and US Venture Partners. The funds raised will primarily be used to accelerate the commercialization of the aprevo® personalized spinal surgery platform for lumbar fusion surgery and to support the development of aprevo® for cervical fusion surgery. It is reported that the aprevo® platform is scheduled to launch in 2025.
Carlsmed is a medical technology company committed to using artificial intelligence technology to provide personalized surgical solutions for patients. Its core product, the aprevo® platform, combines AI technology with advanced medical equipment to offer doctors a more precise and efficient spinal surgery plan. Currently, the platform has been successfully applied to lumbar fusion surgery and has achieved significant treatment results.
The lead investors of this round, B Capital and US Venture Partners, expressed that they are very optimistic about Carlsmed’s development prospects and believe that Carlsmed’s products and technology will have a profound impact on the medical field. A partner at B Capital said, “Carlsmed is changing the way spinal surgery is performed, making it more precise and efficient. We believe that Carlsmed’s technology will become an important trend in the future medical field.”
Carlsmed’s CEO stated that the funds from this round will primarily be used to drive the commercialization of the aprevo® platform and to develop new products. He also said that Carlsmed will continue to commit to the research and development of advanced AI medical technology to provide patients with more personalized surgical solutions.
As AI technology continues to penetrate the medical field, Carlsmed’s development potential is widely recognized. The success of this round of financing not only provides Carlsmed with sufficient capital support but also lays a solid foundation for its future development.
【来源】https://www.businesswire.com/news/home/20240318820510/en/Carlsmed-Raises-52.5M-in-Series-C-Financing-to-Advance-Personalized-Spine-Surgery
Views: 1